MSD
COM:MSD
Merck & Co., Inc.
- Privately Held
news - Jul 17, 2025 - 13:30
Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer
The article discusses Merck & Co., Inc.'s stock performance, challenges with its GARDASIL vaccine in China, and Jim Cramer's analysis of its Verona acquisition and drug pipeline. Cramer asserts the deal is unlikely to face antitrust action and highlights Merck's robust portfolio to offset KEYTRUDA patent expiration risks.
finance.yahoo.comnews - Jul 16, 2025 - 23:45
Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK)
The article compares Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD) as dividend stocks, highlighting MRK's superior dividend growth streak, higher recent dividend increase, and better PEGY ratio. While both have similar payout ratios, GILD's inventory management is noted as stronger, but MRK faces demand issues for its Gardasil vaccine.
seekingalpha.comnews - Jul 15, 2025 - 21:56
Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer
The article discusses Merck & Co., Inc.'s stock performance, including a 15% year-to-date loss and a 16.8% drop in February due to challenges with its GARDASIL vaccine in China and missed earnings forecasts. Jim Cramer highlights Merck's robust drug portfolio and Verona acquisition, stating the deal is unlikely to face antitrust action. He also emphasizes Merck's $50 billion drug pipeline and COPD franchise as key growth drivers.
insidermonkey.comnews - Jul 09, 2025 - 23:41
Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda
Merck announced a $10 billion acquisition of UK-based Verona Pharma to diversify beyond its blockbuster cancer drug Keytruda, which faces patent expiry in 2028. The deal includes Verona's drug Ohtuvayre, a treatment for chronic obstructive pulmonary disease, expected to generate $3 billion in annual revenue by the 2030s. The acquisition follows Merck's previous deals and aims to mitigate revenue risks from Keytruda's declining sales.
reuters.comnews - Jul 09, 2025 - 12:45
Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda
Merck, a U.S. pharmaceutical company, announced a $10 billion acquisition of Verona Pharma, a UK-based biotech firm, to diversify its portfolio beyond its blockbuster cancer drug Keytruda. The deal adds Ohtuvayre, an inhaled treatment for COPD, to Merck's pipeline, with potential annual revenue exceeding $3 billion. The acquisition follows Merck's previous deals, including the $11.5 billion purchase of Acceleron, and is its largest since 2023. Analysts note the strategic move to mitigate Keytruda's patent expirations in 2028.
cnbc.comDescription
Merck & Co., Inc., known as MSD outside the United States and Canada, is a global healthcare leader that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company focuses on scientific excellence and innovation to improve and save lives around the world.